Sogen Data · Datasets · 数据专题
肺癌复发轴数据集锦
单细胞 · bulk 转录组
本专题承自 Sogen Data 数据整理体系,逐条人工复核,附研究设计、样本量、平台与 GEO/PubMed 直达链接。
人源单细胞
Human · Single-cell
-
01 GSE229253 对早期肺癌患者肿瘤组织及匹配的邻近正常肺组织进行单核 RNA 测序,分析其转录组特征以预测疾病复发。研究对象为接受 R0 切除术并伴有淋巴结清扫的 143 名患者,样本类型包括肿瘤(Tumor)和肺邻近正常组织(Lung adjacent normal),采用 10x Genomics 平台的单核 RNA 测序技术,比较复发(Recurrence)与非复发(NoRecurrence)状态下的转录组差异,并区分系统性(Systemic)和继发性原发性(SecondaryPrimary)进展类型。
设计对早期肺癌患者肿瘤组织及匹配的邻近正常肺组织进行单核 RNA 测序,分析其转录组特征以预测疾病复发。研究对象为接受 R0 切除术并伴有淋巴结清扫的 143 名患者,样本类型包括肿瘤(Tumor)和肺邻近正常组织(Lung adjacent normal),采用 10x Genomics 平台的单核 RNA 测序技术,比较复发(Recurrence)与非复发(NoRecurrence)状态下的转录组差异,并区分系统性(Systemic)和继发性原发性(SecondaryPrimary)进展类型。
摘要Single nuclei RNA analysis of adjacent normal tissue to predict recurrence in lung cancer patients
-
02 GSE353299 对EGFR突变型肺腺癌患者在治疗前、osimertinib治疗后残留疾病和进展阶段的肺组织样本进行单细胞RNA测序,分析KRT17+与KRT17-细胞的数量差异。
设计对EGFR突变型肺腺癌患者在治疗前、osimertinib治疗后残留疾病和进展阶段的肺组织样本进行单细胞RNA测序,分析KRT17+与KRT17-细胞的数量差异。
摘要In this study, we leveraged single cell RNA sequencing to quantify the number of KRT17+ and KRT17- cells that exist in human patients at key clinical timepoints (treatment naive, residual disease, and progression). These data were used to extend our findings regarding KRT17+ drug tolerant persisters.
-
03 GSE299684 对复发性小细胞肺癌(SCLC)患者肺部及邻近部位活检和手术切除样本进行单细胞 RNA 测序,识别复发性疾病中独特的细胞群体,包括表达 YAP1 和 AXL 的细胞。
设计对复发性小细胞肺癌(SCLC)患者肺部及邻近部位活检和手术切除样本进行单细胞 RNA 测序,识别复发性疾病中独特的细胞群体,包括表达 YAP1 和 AXL 的细胞。
摘要Purpose: SCLC is an aggressive high-grade neuroendocrine carcinoma (hgNEC) known for its dismal prognosis, with only half of patients with ES-SCLC surviving even one year after diagnosis. Platinum-based doublet chemotherapy continues to be the mainstay of standard of care (SOC), with the addition of immune checkpoint blockade (ICB) improving overall survival by only two months. Few studies have analyzed patient specimens from relapsed SCLC. Experimental design: To better define the biology of relapsed SCLC, we analyzed core needle biopsies and surgical resections from SCLC patients by single-cell (sc)RNAseq. The objectives of this study were to identify unique cell populations present in relapsed disease, including those expressing YAP1 and AXL.
人源bulk 转录组
Human · Bulk RNA-seq
-
01 GSE68465 对442例肺腺癌样本进行基因表达分析,评估基于基因表达的预后模型在多中心、盲法验证中的表现,比较基因表达单独或结合临床协变量(分期、年龄、性别)对总生存期的预测能力。
设计对442例肺腺癌样本进行基因表达分析,评估基于基因表达的预后模型在多中心、盲法验证中的表现,比较基因表达单独或结合临床协变量(分期、年龄、性别)对总生存期的预测能力。
摘要Here we report a large, training*testing, multi-site, blinded validation study to characterize the performance of several prognostic models based on gene expression for 442 lung adenocarcinomas. The hypotheses proposed examined whether microarray measurements of gene expression either alone or combined with basic clinical covariates (stage, age, sex) could be used to predict overall survival in lung cancer subjects. Several models examined produced risk scores that substantially correlated with actual subject outcome. Most methods performed better with clinical data, supporting the combined use of clinical and molecular information when building prognostic models for early-stage lung cancer. This study also provides the largest available set of microarray data with extensive pathological and clinical annotation for lung adenocarcinomas.
-
02 GSE30219 对肺部肿瘤样本进行全基因组表达分析,识别与肺癌复发相关的‘非上下文’基因表达特征,比较不同基因表达模式与患者预后的关系。
设计对肺部肿瘤样本进行全基因组表达分析,识别与肺癌复发相关的‘非上下文’基因表达特征,比较不同基因表达模式与患者预后的关系。
摘要An unexplored consequence of epigenetic alterations associated with cancer is the ectopic expression of tissue-restricted genes. Here, a new strategy was developed to decipher genome-wide expression data in search for these “off-context” gene activations, which consisted first, in identifying a large number of tissue-specific genes normally epigenetically silenced in most somatic cells and second, in using them as cancer biomarkers on an “on/off” basis. Applying this concept to analyze whole-genome transcriptome data in lung cancer, we discovered a specific group of 26 genes whose expression was a strong and independent predictor of poor prognosis in our cohort of 293 lung tumours, as well as in two independent external populations. In addition, these 26 classifying genes enabled us to isolate a homogenous group of metastatic-prone highly aggressive tumours, whose characteristic gene expression profile revealed a high proliferative potential combined to a significant decrease in immune and signaling functions. This work illustrates a new approach for a personalized management of cancer, with applications to any cancer type.
-
03 GSE31210 对226例病理分期I-II的原发性肺腺癌样本进行全基因组表达谱分析,识别ALK阳性及EGFR/KRAS/ALK阴性肺腺癌中上调的基因。将79例无EGFR和KRAS突变的肺腺癌病例分为ALK阳性ADC(11例)、GroupA三阴性ADC(36例)和GroupB三阴性ADC(32例),通过174个基因的表达进行无监督聚类。检测方式为基因表达分析,主要比较ALK阳性ADC与三阴性ADC组间的差异。
设计对226例病理分期I-II的原发性肺腺癌样本进行全基因组表达谱分析,识别ALK阳性及EGFR/KRAS/ALK阴性肺腺癌中上调的基因。将79例无EGFR和KRAS突变的肺腺癌病例分为ALK阳性ADC(11例)、GroupA三阴性ADC(36例)和GroupB三阴性ADC(32例),通过174个基因的表达进行无监督聚类。检测方式为基因表达分析,主要比较ALK阳性ADC与三阴性ADC组间的差异。
摘要Identification of genes up-regulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. To elucidate molecular characteristics of lung adenocarcinomas (ADCs) with ALK mutations and those without EGFR, KRAS and ALK mutations, 226 primary lung ADCs of pathological stage I-II, examined for the status of EGFR, KRAS and ALK mutations, were subjected to genome-wide expression profiling, and genes up-regulated in lung ADCs with ALK mutations and those without EGFR, KRAS and ALK mutations were identified. One hundred and seventy-four genes, including ALK, were selected as being up-regulated specifically in 79 lung ADCs without EGFR and KRAS mutations. These 79 cases were divided into: 11 cases of ALK-positive ADCs, 36 cases of group A triple-negative ADCs, and 32 cases of group B triple-negative ADCs, by unsupervised clustering according to the expression of the 174 genes. In ALK-positive ADCs, 30 genes, including ALK itself and GRIN2A, were significantly overexpressed. Group A triple-negative ADC cases showed significantly worse prognoses for relapse and death than ADC cases with EGFR, KRAS or ALK mutations and group B triple-negative ADC cases. Nine genes were identified as being significantly up-regulated in group A triple-negative ADC cases and critical for predicting their prognosis. The nine genes included DEPDC1, which had been identified as a candidate diagnostic and therapeutic target in bladder and breast cancers. Genes discriminating this group of ADCs will be useful for selection of patients who will benefit from adjuvant chemotherapy after surgical resection of stage I-II triple-negative ADCs and also informative for the development of molecular targeting therapies for these patients.
-
04 GSE50081 对181例早期非小细胞肺癌(NSCLC)患者的肿瘤组织进行RNA表达谱分析,评估15基因预后分类器的临床价值。研究对象为Stage I和II NSCLC病例,采集自University Health Network(UHN181),采用Kaplan-Meier方法估计三年总生存率,并通过log-rank检验和Cox比例风险模型分析分类器的预后效果。
设计对181例早期非小细胞肺癌(NSCLC)患者的肿瘤组织进行RNA表达谱分析,评估15基因预后分类器的临床价值。研究对象为Stage I和II NSCLC病例,采集自University Health Network(UHN181),采用Kaplan-Meier方法估计三年总生存率,并通过log-rank检验和Cox比例风险模型分析分类器的预后效果。
摘要Background: Patients with early stage non-small cell lung carcinoma (NSCLC) may benefit from treatments based on more accurate prognosis. A 15-gene prognostic classifier for NSCLC was identified from mRNA expression profiling of tumor samples from the NCIC CTG JBR.10 trial. Here, we assessed its value in an independent set of cases. Methods: Expression profiling was performed on RNA from frozen, resected tumor tissues corresponding to 181 Stage I and II NSCLC cases collected at University Health Network (UHN181). Kaplan-Meier methodology was used to estimate three year overall survival probabilities and the prognostic effect of the classifier was assessed using log-rank testing. Cox proportional hazards model evaluated the signature's effect adjusting for clinical prognostic factors. Results: Expression data of the 15-gene classifier stratified UHN181 cases into high and low-risk subgroups with significantly different overall survival (HR=1.92, 95% CI: 1.15-3.23, p=0.012). Its strength as a prognostic classifier was superior to stage alone (HR=1.52, 95% CI: 0.90-2.55, p-value=0.11). In subgroup analysis, this classifier predicted survival in 127 Stage I patients (HR=2.17, 95% CI: 1.12-4.20, p=0.018) and the smaller subgroup of 48 Stage IA patients (HR=5.61, 95% CI: 1.19-26.45, p=0.014. The signature was prognostic for both adenocarcinoma and squamous cell carcinoma cases (HR= 1.76, p-value=0.058; HR= 4.19, p-value=0.045, respectively). Conclusions: The prognostic accuracy of a 15-gene classifier was validated in an independent cohort of 181 early stage NSCLC samples including Stage IA cases and in different NSCLC histologic subtypes.
-
05 GSE8894 对术后非小细胞肺癌患者进行复发风险预测研究,采集冷冻保存的原发性肺癌组织进行微阵列表达分析,通过 log-rank 检验筛选出 5% 显著水平的 87 个基因,进一步通过 PTQ-PCR 验证其中 18 个基因的表达,结合临床参数采用逐步变量选择法构建包含 6 个基因(CALB1, MMP7, SLC1A7, GSTA1, CCL19, IFI44)及 pStage 和细胞分化的复发预测模型,验证结果显示模型在两个独立队列中表现良好。
设计对术后非小细胞肺癌患者进行复发风险预测研究,采集冷冻保存的原发性肺癌组织进行微阵列表达分析,通过 log-rank 检验筛选出 5% 显著水平的 87 个基因,进一步通过 PTQ-PCR 验证其中 18 个基因的表达,结合临床参数采用逐步变量选择法构建包含 6 个基因(CALB1, MMP7, SLC1A7, GSTA1, CCL19, IFI44)及 pStage 和细胞分化的复发预测模型,验证结果显示模型在两个独立队列中表现良好。
摘要Background: One of the main fields of lung cancer research is identifying patients who are at high risk of post-resection recurrence. Individual recurrence risk evaluation by accurate but simple and reproducible method is needed for the clinical practice. Results: The log-rank test and further selection by our criteria of assayability generated 87 genes from microarray data with significant level 5%. Of these, by PTQ-PCR, the expression of most significant 18 genes was obtained. Using these gene expression information and clinical parameters, by stepwise variable selection method, the recurrence prediction model, which composed of 6 genes (CALB1, MMP7, SLC1A7, GSTA1, CCL19, IFI44) and pStage and cell differentiation, were developed. Validation into the two independent cohorts showed good results of the proposed model (p=0.0314, 0.0305, respectively). The predicted median recurrence-free survival times for each patient were reflected real ones well. Conclusions: Our method of individualized recurrence risk prediction is accurate, technically simple and reproducible to be used in clinical practice. Therefore, it would be useful in customizing the lung cancer management strategies. Keywords: Recurrence Free Survival Analysis
-
06 GSE154286 对非小细胞肺癌(NSCLC)患者肿瘤活检样本进行基因表达分析,比较化疗前(诊断时)与化疗后进展阶段的差异。采集100例化疗前肿瘤活检和33例化疗后进展活检样本,其中29例患者提供配对样本。检测201个癌症及免疫相关基因的表达水平,分析免疫基因簇变化及配对样本中特定基因的表达差异。
设计对非小细胞肺癌(NSCLC)患者肿瘤活检样本进行基因表达分析,比较化疗前(诊断时)与化疗后进展阶段的差异。采集100例化疗前肿瘤活检和33例化疗后进展活检样本,其中29例患者提供配对样本。检测201个癌症及免疫相关基因的表达水平,分析免疫基因簇变化及配对样本中特定基因的表达差异。
摘要Background: Over the past few years, immune checkpoint inhibitors have changed the therapeutic landscape of non-small-cell lung cancer (NSCLC). Response to immune checkpoint inhibitors correlates with a pre-existing anti-tumoral immune response. Checkpoint inhibitors have been introduced as second line therapy and are only very recently used as monotherapy or in combination with chemotherapy as first line treatment of NSCLC. However, the effect of conventional first line platinum-based chemotherapy on the immune infiltrate in the tumor is largely unknown. Methods: We measured the gene expression of a custom set of 201 cancer- and immune-related genes in 100 NSCLC tumor biopsies collected before chemotherapy and 33 re-biopsies after platinum-based chemotherapy at the time point of progression. For 29 patients matched pre- and post-chemotherapy samples could be evaluated. Results: We identified a cluster of 47 co-expressed immune genes, including PDCD1 (PD1) and CD274 (PD-L1), along with three other co-expression clusters. Chemotherapy decreased the average gene expression of the immune cluster while no effect was observed on the other three cluster. Within this immune cluster, CTLA4, LAG3, TNFRSF18, CD80 and FOXP3 were found to be significantly decreased in patient-matched samples after chemotherapy. Conclusion: Our results suggest that conventional platinum-based chemotherapy negatively impacts the immune microenvironment at the time point of secondary progression.
-
07 GSE13213 通过全基因组表达谱分析训练集中的 60 例肺腺癌患者,识别出与复发相关的 82 个探针组成的分子特征(RRS-82)。随后使用 27 例腺癌患者的完全盲法测试集验证 RRS-82 在预测高复发概率患者中的稳健性,结果显示高风险 RRS-82 与极差预后显著相关,无论疾病分期。此外,使用 30 例 I 期患者的独立队列进一步验证 RRS-82 的判别能力。
设计通过全基因组表达谱分析训练集中的 60 例肺腺癌患者,识别出与复发相关的 82 个探针组成的分子特征(RRS-82)。随后使用 27 例腺癌患者的完全盲法测试集验证 RRS-82 在预测高复发概率患者中的稳健性,结果显示高风险 RRS-82 与极差预后显著相关,无论疾病分期。此外,使用 30 例 I 期患者的独立队列进一步验证 RRS-82 的判别能力。
摘要We identified a relapse-related molecular signature represented by 82 probes (RRS-82) through genome-wide expression profiling analysis of a training set of 60 patients. The robustness of RRS-82 in the selection of patients with a high probability of relapse was then validated with a completely blinded test set of 27 adenocarcinoma patients, showing a clear association of high risk RRS-82 with very poor patient prognosis regardless of disease stage. The discriminatory power of RRS-82 was further validated using an additional independent cohort of 30 Stage I patients who underwent surgery at a distinct period of time. Keywords: Disease state analysis
-
08 GSE32863 对58例肺腺癌及58例匹配的邻近非肿瘤肺组织进行宏观解剖,提取总RNA并使用Illumina HumanWG-6 v3.0表达芯片分析,比较肿瘤与非肿瘤肺组织的基因表达差异。
设计对58例肺腺癌及58例匹配的邻近非肿瘤肺组织进行宏观解剖,提取总RNA并使用Illumina HumanWG-6 v3.0表达芯片分析,比较肿瘤与非肿瘤肺组织的基因表达差异。
摘要Gene expression profiling of 60 lung adenocarcinoma tumors and their matched histologically normal adjacent lung tissue samples were analyzed using Illumina HumanWG-6 v3.0 expression beadchip. We integrated these data with DNA methylation profiles of the same samples to identify potential DNA methylation regulated genes. Lung cancer is the leading cause of cancer death worldwide and adenocarcinoma is its most common histological subtype. Clinical and molecular evidence indicates that lung adenocarcinoma is a heterogeneous disease, which has important implications for treatment. Here we performed genome-scale DNA methylation profiling using the Illumina Infinium HumanMethylation27 platform on 59 matched lung adenocarcinoma/non-tumor lung samples, with genome-scale verification on an independent set of tissues. We identified 766 genes showing altered DNA methylation between tumors and non-tumor lung. By integrating DNA methylation and mRNA expression data, we identified 164 hypermethylated genes showing concurrent downregulation, and 57 hypomethylated genes showing increased expression. Integrated pathways analysis indicates that these genes are involved in cell differentiation, epithelial to mesenchymal transition, RAS and WNT signaling pathways and cell cycle regulation, among others. Comparison of DNA methylation profiles between lung adenocarcinomas of current and never-smokers showed modest differences, identifying only LGALS4 as significantly hypermethylated and downregulated in smokers. LGALS4, encoding a galactoside-binding protein involved in cell-cell and cell-matrix interactions, was recently shown to be a tumor-suppressor in colorectal cancer. Unsupervised analysis of the DNA methylation data identified two tumor subgroups, one of which showed increased DNA methylation and was significantly associated with KRAS mutation and to a lesser extent, with smoking. Our analysis lays the groundwork for further molecular studies of lung adenocarcinoma by providing new candidate DNA methylation biomarkers for early detection, identifying novel molecular alterations potentially involved in lung adenocarcinoma development/progression, and describing an epigenetic subgroup of lung adenocarcinoma associated with KRAS mutation.
-
09 GSE7339 对术后肿瘤复发与非复发的肺腺癌组织进行基因表达分析,采集17例复发和23例非复发样本,采用微阵列技术检测总RNA表达差异。
设计对术后肿瘤复发与非复发的肺腺癌组织进行基因表达分析,采集17例复发和23例非复发样本,采用微阵列技术检测总RNA表达差异。
摘要We used microarrays to detail the clinical features in patients with lung cancer and identified genes differentially expressed between non-tumorous tissue and cancer tissue of lung. Keywords: disease state analysis
-
10 GSE117049 将肺腺癌(LUAD)患者肿瘤组织与正常肺组织进行比较,同时对A549 LUAD细胞系在常氧和缺氧条件下进行培养,并对NLUCAT1敲除的A549克隆在常氧和缺氧条件下进行比较,采集RNA进行高通量测序,分析不同条件下lncRNA的表达变化及其与氧化应激的关系。
设计将肺腺癌(LUAD)患者肿瘤组织与正常肺组织进行比较,同时对A549 LUAD细胞系在常氧和缺氧条件下进行培养,并对NLUCAT1敲除的A549克隆在常氧和缺氧条件下进行比较,采集RNA进行高通量测序,分析不同条件下lncRNA的表达变化及其与氧化应激的关系。
摘要Lung cancer is the leading cause of cancer death worldwide, with poor prognosis and a high rate of recurrence despite early surgical removal. Hypoxic regions within tumors represent sources of aggressiveness and resistance to therapy. While long non-coding RNAs (lncRNAs) are increasingly recognized as major gene expression regulators, their regulation and function following hypoxic stress are still largely unexplored. Combining profiling studies on early stage lung adenocarcinomas (LUAD) biopsies and on A549 LUAD cell lines cultured in normoxic or hypoxic conditions, we identified a subset of lncRNAs that are both correlated with the hypoxic status of tumors and regulated by hypoxia in vitro. We focused on a new transcript, NLUCAT1 that is strongly upregulated by hypoxia in vitro and correlated with hypoxic markers and poor prognosis in LUADs. Full molecular characterization showed that NLUCAT1 is a large nuclear transcript composed of 6 exons and mainly regulated by NF-ĸB and NRF2 transcription factors. CRISPR-Cas9-mediated invalidation of NLUCAT1 revealed a decrease in proliferative and invasive properties, an increase in oxidative stress and a higher sensitivity to cisplatin-induced apoptosis. Transcriptome analysis of NLUCAT1-deficient cells showed repressed genes within the anti-oxidant and/or cisplatin-response networks. We demonstrated that the concomitant knockdown of 4 of these genes, GPX2, GLRX, ALDH3A1 and PDK4, significantly increased ROS-dependent caspase activation, thus partially mimicking the consequences of NLUCAT1 inactivation in LUAD cells. Overall, we demonstrate that NLUCAT1 contributes to an aggressive phenotype in early-stage hypoxic tumors suggesting it may represent a new potential therapeutic target in LUADs. This SuperSeries is composed of the SubSeries listed below.
-
11 GSE116959 研究对象为57例LUAD患者及11例同源患者周围正常肺组织样本,采集自2004至2010年住院的法国尼斯大学医院肺科与胸外科患者。所有肿瘤样本依据第7版pTNM分类及最后NSCLC组织学分类确诊,正常样本取自距肿瘤3cm区域。采用TRIzol试剂提取总RNA,通过微阵列平台GPL17077进行表达谱分析,比较肿瘤组织与对应正常组织的转录组差异。
设计研究对象为57例LUAD患者及11例同源患者周围正常肺组织样本,采集自2004至2010年住院的法国尼斯大学医院肺科与胸外科患者。所有肿瘤样本依据第7版pTNM分类及最后NSCLC组织学分类确诊,正常样本取自距肿瘤3cm区域。采用TRIzol试剂提取总RNA,通过微阵列平台GPL17077进行表达谱分析,比较肿瘤组织与对应正常组织的转录组差异。
摘要RNA was extracted from 57 LUAD patients hospitalized from 2004 to 2010 at the Pasteur Hospital (Departments of Pulmonary Medicine, and Thoracic Surgery, CHU de Nice, France) and 11 normal lung tissue specimens taken from areas at standard distance (3 cm) from the same cohort of patients.The diagnosis of LUAD patients was based on examination of all tumor specimens using the 7th pTNM classification and on the last histological classification of NSCLC. Written informed consent was obtained from participants after explaining the nature of the study, which was approved by the research ethics board of the Nice University hospital and was performed according to the guidelines of the Declaration of Helsinki. The main clinical and pathological data are summarized. Enrollment of patients in our study was conditioned by stringent criteria such as obtained signed consent, availability of resected surgical specimens, good quality RNA and time of follow-up for surviving patients (min 40 months for surviving patients).
-
12 GSE5843 对48例完全切除的肺腺癌患者进行基因表达分析,比较术后至少36个月无病生存者与18个月内复发者的基因表达谱,以识别与肺腺癌复发相关的基因签名。
设计对48例完全切除的肺腺癌患者进行基因表达分析,比较术后至少36个月无病生存者与18个月内复发者的基因表达谱,以识别与肺腺癌复发相关的基因签名。
摘要Lung cancer remains the leading cause of cancer death worldwide. Overall 5-year survival is about 10-15% and despite curative intent surgery, treatment failure is primarily due to recurrent disease. Conventional prognostic markers are unable to determine which patients with completely resected disease within each stage group are likely to relapse. To identify a gene signature associated with recurrent adenocarcinoma (AC) of lung, we analyzed primary tumour gene expression for a total of 48 stage I ACs on 22,323 element microarrays, comparing expression profiles for individuals who remained disease-free for a minimum of 36 months with those from individuals whose disease recurred within 18 months of complete resection. Genome-wide profiling has revealed a distinct gene expression profile for recurrent lung AC which may be clinically useful as a prognostic tool. Keywords: non-small cell lung carcinoma, squamous cell, tumor recurrence, expression profiling
-
13 GSE7880 对20例原发性非小细胞肺癌(10例腺癌、10例鳞癌)患者与23例IIIB/IV期非小细胞肺癌(15例腺癌、8例鳞癌)患者的肺组织进行基因表达比较,采用Human HG Focus Array微阵列平台检测,使用方差稳定变换(VSN)归一化并结合显著性分析(SAM)识别差异表达基因,比较原发与复发样本间基因表达模式差异。
设计对20例原发性非小细胞肺癌(10例腺癌、10例鳞癌)患者与23例IIIB/IV期非小细胞肺癌(15例腺癌、8例鳞癌)患者的肺组织进行基因表达比较,采用Human HG Focus Array微阵列平台检测,使用方差稳定变换(VSN)归一化并结合显著性分析(SAM)识别差异表达基因,比较原发与复发样本间基因表达模式差异。
摘要To identify genes associated with lung cancer progression, we examined gene expression profiles of tumor cells from 20 patients with primary, untreated non-small cell lung cancer (10 adenocarcinomas (AC) and 10 squamous cell carcinomas (SCC)) in comparison to lung tissue of 23 patients with stage IIIB or stage IV non-small cell lung cancer (15 AC and 8 SCC). Bronchoscopical biopsies from patient with recurrent lung tumor were taken after initial treatment. Cancer cells were isolated using laser capture microdissection in order to obtain pure samples of tumor cells. For expression analysis, microarrays covering 8793 defined genes (Human HG Focus Array, Affymetrix) were used. Array data were normalized and analysed for significant differences using variance stabilizing transformation (VSN) and significance analysis of microarrays (SAM), respectively. Genes were considered to be up- or down-regulated when the ratio between primary and recurrent tumor samples were at least 1.5-fold differentially expressed with an estimated false discovery rate: < 5%. Based on differentially expressed genes, primary cancer samples could be separated from recurrent tumor samples. We identified 115 and 124 significantly regulates genes in AC and SCC, respectively. For example, in recurrent AC we found increased expression of genes related to the wingless (FZD6, RYK, MYC) and calcium (CALM1, ATB2B1, S100A2) signalling pathways which might play a role in metastasis of tumor cells. Other differentially expressed genes were related to cell cycle (CCND1, CDK2), transcription factors (TTF1, TAF2, YY1), nuclear mRNA splicing and mRNA processing (SFRS1, HNRPL), protein-nucleus import (NUTF2, KPNB1, NUP50) and chromatin modification (HIST1H4C, SMARCC1). In SCC, we found an increased expression of CTNNB1, an important mediator in wingless signalling pathway. Among the down-regulated genes in SCC, the utmost fraction belonged to genes coding for ubiquitin mediated proteolysis (UCHL1, PSMA3, COPS6) and ribosomal proteins (RPS26, RPL7A, RPS15). Other down regulated genes were related to transcription factors (TCEA2, TAF10), nuclear mRNA splicing and mRNA processing (SNRPD2, HNRPM). In conclusion, a distinct pattern of gene expression is found during the progression from primary carcinoma to recurrent NSCLC. Our microarray-based expression profiling revealed interesting novel candidate genes and pathways that may contribute to lung cancer progression. Keywords: Lung cancer, NSCLC, gene expression, progression, Wnt signalling pathway
-
14 GSE9971 将接受手术切除Ia-IIIb期非小细胞肺癌(NSCLC)的患者分为术后2年复发组(R,n=11)与非复发组(NR,n=16),采集其冷冻肿瘤组织进行微阵列分析,比较两组基因表达差异。
设计将接受手术切除Ia-IIIb期非小细胞肺癌(NSCLC)的患者分为术后2年复发组(R,n=11)与非复发组(NR,n=16),采集其冷冻肿瘤组织进行微阵列分析,比较两组基因表达差异。
摘要Study to identify genes associated with NSCLC recurrence in patients not receiving adjuvant chemotherapy. Purpose: Recent clinical trials suggest improvement in survival with adjuvant chemotherapy in non-small cell lung cancer (NSCLC). This study's aim is to identify genes associated with NSCLC recurrence in patients not receiving adjuvant chemotherapy. Experimental design: Banked NSCLC tumors of patients who underwent resection of stage Ia-IIIb disease were identified. Patients were stratified into two groups: recurrent (R, n=11) or non-recurrent (NR, n=16) 2 years after surgery. Microarray profiling and Cox multivariate analysis were performed. Conclusion: Increased CYP3A5 gene expression correlates with NSCLC recurrence and promotes proliferation through mechanisms that may involve, in part, CYP3A5 epoxygenase activity. Keywords: comparison of gene expression profiles for recurrent and non-recurrent cancer
-
15 GSE136961 对21例非小细胞肺癌患者治疗前的组织total RNA进行Oncomine免疫反应面板靶向测序,评估395个免疫相关基因表达及肿瘤突变负担,将患者按是否获得持续临床获益分为持续获益组(DCB,9例)和非持续获益组(NDB,12例),比较两组间基因表达特征差异。
设计对21例非小细胞肺癌患者治疗前的组织total RNA进行Oncomine免疫反应面板靶向测序,评估395个免疫相关基因表达及肿瘤突变负担,将患者按是否获得持续临床获益分为持续获益组(DCB,9例)和非持续获益组(NDB,12例),比较两组间基因表达特征差异。
摘要Immune checkpoint blockade is promising for treating non-small-cell lung cancer (NSCLC). We used multipanel markers to predict the response to immune checkpoint inhibitors (ICIs) by characterizing gene expression signatures or individual genes in patients who showed durable clinical benefit to ICIs. Twenty-one patients with NSCLC treated with single-agent anti-programmed cell death protein (PD)-1 antibody were analyzed and their clinicopathological characteristics and response to ICIs were characterized. Targeted sequencing of tissue-extracted DNA and RNA was performed using the Oncomine Immune Response Research Assay to evaluate 395 genes involved in the immune response and calculate the tumor mutation burden. Nine (43%) showed a durable clinical benefit (DCB), while the remaining 12 (57%) patients showed non-durable benefit (NDB). The M1 and peripheral T cell signatures showed the best performance for discriminating DCB from NDB (sensitivity, specificity, accuracy = 0.89, 1.0, 0.95, respectively). Progression-free survival (PFS) was significantly longer in patients with high M1 signature or high peripheral T cell signature scores. CD137 and PSMB9 mRNA expression was higher in the DCB group than in the NDB group. Patients with high PSMB9 expression showed longer PFS. M1 signature, peripheral T cell signature and high mRNA expression level of CD137 and PSMB9 showed better predictive performance than known biomarkers (PD-L1, tumor infiltrating lymphocytes, tumor mutation burden). M1 and peripheral T cell signature of tumors may enable prediction of durable response and maximize the benefit of ICIs in patients with NSCLC.

课题合作 · 扫码加微信
bioinformaticsboy